P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies

R. Beach, A. M. Gown, M. N. De Peralta-Venturina, A. L. Folpe, H. Yaziji, P. G. Salles, David Grignon, G. R. Fanger, M. B. Amin

Research output: Contribution to journalArticle

158 Citations (Scopus)

Abstract

P504S is a recently described, prostate cancer-specific gene that encodes a protein involved in the beta-oxidation of branched chain fatty acids. A recent study has shown that immunohistochemical detection of P504S gene product is a sensitive and specific marker of prostatic carcinoma in formalin-fixed, paraffin-embedded tissues. We performed a detailed analysis of P504S protein expression in a large series of prostate and bladder specimens with special emphasis on staining in specific morphologic patterns of prostatic adenocarcinoma, posthormonal and radiation therapy cases, and invasive urothelial carcinoma. A total of 366 prostate needle core biopsies from 124 patients with prostate cancer, 10 biopsies from 2 patients without prostate cancer, 28 prostatectomy specimens (16 with specific morphologic patterns, 7 posthormonal therapy and 5 postradiation therapy specimens), 5 bladder specimens with invasive urothelial carcinoma, and a single transurethral resection specimen from a patient with hormonally treated prostate cancer and invasive urothelial carcinoma were stained with P504S monoclonal antibody at a 1:250 dilution using standard heat-induced epitope retrieval and avidin-biotin technique. Extent (0, no staining; 1+, 1-10% staining; 2+, 11-50% staining; 3+, ≥51% staining) and location (luminal, subluminal, and diffuse cytoplasmic) of immunoreactivity in carcinoma and benign tissues were recorded. A total of 153 of 186 biopsies (82%) with prostatic adenocarcinoma stained for P504S. Pseudohyperplastic, atrophic, ductal, and mucinous prostatic carcinomas stained similarly, as did cases treated with hormone or radiotherapy. In 81 of 377 (21%) foci of benign prostatic tissue there was staining that was almost always focal, faint, and noncircumferential. Seminal vesicles did not stain for P504S. Five of six (83%) specimens with invasive urothelial carcinoma had 2+ staining and one case had focal staining. We conclude that immunohistochemistry for P504S has potential utility in the diagnosis of prostate cancer, including those treated by hormones and radiation. Circumferential luminal to subluminal and diffuse cytoplasmic staining is the most specific staining pattern for prostatic carcinoma and is almost never associated with benign prostatic tissue. However, a negative P504S immunostain does not automatically rule out prostate cancer, as 18% of cases were negative. Additionally, occasional benign glands, high-grade prostatic intraepithelial neoplasia, atypical adenomatous hyperplasia, and urothelial carcinoma may express P504S. Therefore, we think that P504S is best used only in conjunction with strict light microscopic correlation and preferably with high molecular weight cytokeratin immunostaining.

Original languageEnglish (US)
Pages (from-to)1588-1596
Number of pages9
JournalAmerican Journal of Surgical Pathology
Volume26
Issue number12
DOIs
StatePublished - Dec 2002
Externally publishedYes

Fingerprint

Needle Biopsy
Staining and Labeling
Carcinoma
Prostatic Neoplasms
Prostate
Urinary Bladder
Adenocarcinoma
Radiotherapy
Hormones
Prostatic Intraepithelial Neoplasia
Large-Core Needle Biopsy
Biopsy
Mucinous Adenocarcinoma
Avidin
Seminal Vesicles
Neoplasm Genes
Prostatectomy
Biotin
Keratins
Paraffin

Keywords

  • AMACR gene
  • Cytokeratins
  • Immunohistochemistry
  • P504S genea-Methylacyl-CoA Racemase gene
  • Prostate carcinoma
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine

Cite this

Beach, R., Gown, A. M., De Peralta-Venturina, M. N., Folpe, A. L., Yaziji, H., Salles, P. G., ... Amin, M. B. (2002). P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. American Journal of Surgical Pathology, 26(12), 1588-1596. https://doi.org/10.1097/00000478-200212000-00006

P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. / Beach, R.; Gown, A. M.; De Peralta-Venturina, M. N.; Folpe, A. L.; Yaziji, H.; Salles, P. G.; Grignon, David; Fanger, G. R.; Amin, M. B.

In: American Journal of Surgical Pathology, Vol. 26, No. 12, 12.2002, p. 1588-1596.

Research output: Contribution to journalArticle

Beach, R, Gown, AM, De Peralta-Venturina, MN, Folpe, AL, Yaziji, H, Salles, PG, Grignon, D, Fanger, GR & Amin, MB 2002, 'P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies', American Journal of Surgical Pathology, vol. 26, no. 12, pp. 1588-1596. https://doi.org/10.1097/00000478-200212000-00006
Beach, R. ; Gown, A. M. ; De Peralta-Venturina, M. N. ; Folpe, A. L. ; Yaziji, H. ; Salles, P. G. ; Grignon, David ; Fanger, G. R. ; Amin, M. B. / P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. In: American Journal of Surgical Pathology. 2002 ; Vol. 26, No. 12. pp. 1588-1596.
@article{21921a6ef51e4e96a91647bdf42a3334,
title = "P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies",
abstract = "P504S is a recently described, prostate cancer-specific gene that encodes a protein involved in the beta-oxidation of branched chain fatty acids. A recent study has shown that immunohistochemical detection of P504S gene product is a sensitive and specific marker of prostatic carcinoma in formalin-fixed, paraffin-embedded tissues. We performed a detailed analysis of P504S protein expression in a large series of prostate and bladder specimens with special emphasis on staining in specific morphologic patterns of prostatic adenocarcinoma, posthormonal and radiation therapy cases, and invasive urothelial carcinoma. A total of 366 prostate needle core biopsies from 124 patients with prostate cancer, 10 biopsies from 2 patients without prostate cancer, 28 prostatectomy specimens (16 with specific morphologic patterns, 7 posthormonal therapy and 5 postradiation therapy specimens), 5 bladder specimens with invasive urothelial carcinoma, and a single transurethral resection specimen from a patient with hormonally treated prostate cancer and invasive urothelial carcinoma were stained with P504S monoclonal antibody at a 1:250 dilution using standard heat-induced epitope retrieval and avidin-biotin technique. Extent (0, no staining; 1+, 1-10{\%} staining; 2+, 11-50{\%} staining; 3+, ≥51{\%} staining) and location (luminal, subluminal, and diffuse cytoplasmic) of immunoreactivity in carcinoma and benign tissues were recorded. A total of 153 of 186 biopsies (82{\%}) with prostatic adenocarcinoma stained for P504S. Pseudohyperplastic, atrophic, ductal, and mucinous prostatic carcinomas stained similarly, as did cases treated with hormone or radiotherapy. In 81 of 377 (21{\%}) foci of benign prostatic tissue there was staining that was almost always focal, faint, and noncircumferential. Seminal vesicles did not stain for P504S. Five of six (83{\%}) specimens with invasive urothelial carcinoma had 2+ staining and one case had focal staining. We conclude that immunohistochemistry for P504S has potential utility in the diagnosis of prostate cancer, including those treated by hormones and radiation. Circumferential luminal to subluminal and diffuse cytoplasmic staining is the most specific staining pattern for prostatic carcinoma and is almost never associated with benign prostatic tissue. However, a negative P504S immunostain does not automatically rule out prostate cancer, as 18{\%} of cases were negative. Additionally, occasional benign glands, high-grade prostatic intraepithelial neoplasia, atypical adenomatous hyperplasia, and urothelial carcinoma may express P504S. Therefore, we think that P504S is best used only in conjunction with strict light microscopic correlation and preferably with high molecular weight cytokeratin immunostaining.",
keywords = "AMACR gene, Cytokeratins, Immunohistochemistry, P504S genea-Methylacyl-CoA Racemase gene, Prostate carcinoma, Urothelial carcinoma",
author = "R. Beach and Gown, {A. M.} and {De Peralta-Venturina}, {M. N.} and Folpe, {A. L.} and H. Yaziji and Salles, {P. G.} and David Grignon and Fanger, {G. R.} and Amin, {M. B.}",
year = "2002",
month = "12",
doi = "10.1097/00000478-200212000-00006",
language = "English (US)",
volume = "26",
pages = "1588--1596",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies

AU - Beach, R.

AU - Gown, A. M.

AU - De Peralta-Venturina, M. N.

AU - Folpe, A. L.

AU - Yaziji, H.

AU - Salles, P. G.

AU - Grignon, David

AU - Fanger, G. R.

AU - Amin, M. B.

PY - 2002/12

Y1 - 2002/12

N2 - P504S is a recently described, prostate cancer-specific gene that encodes a protein involved in the beta-oxidation of branched chain fatty acids. A recent study has shown that immunohistochemical detection of P504S gene product is a sensitive and specific marker of prostatic carcinoma in formalin-fixed, paraffin-embedded tissues. We performed a detailed analysis of P504S protein expression in a large series of prostate and bladder specimens with special emphasis on staining in specific morphologic patterns of prostatic adenocarcinoma, posthormonal and radiation therapy cases, and invasive urothelial carcinoma. A total of 366 prostate needle core biopsies from 124 patients with prostate cancer, 10 biopsies from 2 patients without prostate cancer, 28 prostatectomy specimens (16 with specific morphologic patterns, 7 posthormonal therapy and 5 postradiation therapy specimens), 5 bladder specimens with invasive urothelial carcinoma, and a single transurethral resection specimen from a patient with hormonally treated prostate cancer and invasive urothelial carcinoma were stained with P504S monoclonal antibody at a 1:250 dilution using standard heat-induced epitope retrieval and avidin-biotin technique. Extent (0, no staining; 1+, 1-10% staining; 2+, 11-50% staining; 3+, ≥51% staining) and location (luminal, subluminal, and diffuse cytoplasmic) of immunoreactivity in carcinoma and benign tissues were recorded. A total of 153 of 186 biopsies (82%) with prostatic adenocarcinoma stained for P504S. Pseudohyperplastic, atrophic, ductal, and mucinous prostatic carcinomas stained similarly, as did cases treated with hormone or radiotherapy. In 81 of 377 (21%) foci of benign prostatic tissue there was staining that was almost always focal, faint, and noncircumferential. Seminal vesicles did not stain for P504S. Five of six (83%) specimens with invasive urothelial carcinoma had 2+ staining and one case had focal staining. We conclude that immunohistochemistry for P504S has potential utility in the diagnosis of prostate cancer, including those treated by hormones and radiation. Circumferential luminal to subluminal and diffuse cytoplasmic staining is the most specific staining pattern for prostatic carcinoma and is almost never associated with benign prostatic tissue. However, a negative P504S immunostain does not automatically rule out prostate cancer, as 18% of cases were negative. Additionally, occasional benign glands, high-grade prostatic intraepithelial neoplasia, atypical adenomatous hyperplasia, and urothelial carcinoma may express P504S. Therefore, we think that P504S is best used only in conjunction with strict light microscopic correlation and preferably with high molecular weight cytokeratin immunostaining.

AB - P504S is a recently described, prostate cancer-specific gene that encodes a protein involved in the beta-oxidation of branched chain fatty acids. A recent study has shown that immunohistochemical detection of P504S gene product is a sensitive and specific marker of prostatic carcinoma in formalin-fixed, paraffin-embedded tissues. We performed a detailed analysis of P504S protein expression in a large series of prostate and bladder specimens with special emphasis on staining in specific morphologic patterns of prostatic adenocarcinoma, posthormonal and radiation therapy cases, and invasive urothelial carcinoma. A total of 366 prostate needle core biopsies from 124 patients with prostate cancer, 10 biopsies from 2 patients without prostate cancer, 28 prostatectomy specimens (16 with specific morphologic patterns, 7 posthormonal therapy and 5 postradiation therapy specimens), 5 bladder specimens with invasive urothelial carcinoma, and a single transurethral resection specimen from a patient with hormonally treated prostate cancer and invasive urothelial carcinoma were stained with P504S monoclonal antibody at a 1:250 dilution using standard heat-induced epitope retrieval and avidin-biotin technique. Extent (0, no staining; 1+, 1-10% staining; 2+, 11-50% staining; 3+, ≥51% staining) and location (luminal, subluminal, and diffuse cytoplasmic) of immunoreactivity in carcinoma and benign tissues were recorded. A total of 153 of 186 biopsies (82%) with prostatic adenocarcinoma stained for P504S. Pseudohyperplastic, atrophic, ductal, and mucinous prostatic carcinomas stained similarly, as did cases treated with hormone or radiotherapy. In 81 of 377 (21%) foci of benign prostatic tissue there was staining that was almost always focal, faint, and noncircumferential. Seminal vesicles did not stain for P504S. Five of six (83%) specimens with invasive urothelial carcinoma had 2+ staining and one case had focal staining. We conclude that immunohistochemistry for P504S has potential utility in the diagnosis of prostate cancer, including those treated by hormones and radiation. Circumferential luminal to subluminal and diffuse cytoplasmic staining is the most specific staining pattern for prostatic carcinoma and is almost never associated with benign prostatic tissue. However, a negative P504S immunostain does not automatically rule out prostate cancer, as 18% of cases were negative. Additionally, occasional benign glands, high-grade prostatic intraepithelial neoplasia, atypical adenomatous hyperplasia, and urothelial carcinoma may express P504S. Therefore, we think that P504S is best used only in conjunction with strict light microscopic correlation and preferably with high molecular weight cytokeratin immunostaining.

KW - AMACR gene

KW - Cytokeratins

KW - Immunohistochemistry

KW - P504S genea-Methylacyl-CoA Racemase gene

KW - Prostate carcinoma

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0036891945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036891945&partnerID=8YFLogxK

U2 - 10.1097/00000478-200212000-00006

DO - 10.1097/00000478-200212000-00006

M3 - Article

C2 - 12459625

AN - SCOPUS:0036891945

VL - 26

SP - 1588

EP - 1596

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 12

ER -